A Phase III Study of MG-K10 in Adolescents With Moderate-to-Severe Atopic Dermatitis

NCT07540442 · clinicaltrials.gov ↗

PHASE3

Phase

NOT_YET_RECRUITING

Status

180

Enrollment

INDUSTRY

Sponsor class

Conditions

Dermatitis, Atopic

Interventions

DRUG: MG-K10 Injection (Humanized Monoclonal Antibody)
DRUG: Placebo for MG-K10

Sponsor

Shanghai Mabgeek Biotech.Co.Ltd